Clinical Trial Update: TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating allogeneic CD19-targeting CAR-T cells with SPPL3 gene knockout for relapsed/refractory B-cell lymphoma, currently recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Allogeneic CD19-targeting CAR-T cell therapy with SPPL3 knockout (TCR Reserved and Power3)

Snippet

Sponsor: Chinese PLA General Hospital | Conditions: Non-hodgkin Lymphoma | Phase 1, Phase 2 | Status: RECRUITING